Transgene and BioInvent’s BT-001 oncolytic virus
First clinical data presented at ESMO 2024 show that BT-001 induces tumor size reduction in patients with treatment failure In a patient with heavily pretreated sarcoma, BT-001 has the ability to reheat tumors, increasing T cell infiltration and PD(L)-1 expression in tumors In combination with KEYTRUDA® (pembrolizumab), the first signs of efficacy with clinical responses … Read more